Skip to main content
MedPathMedPath Home
Clinical Trials/DRKS00021705
DRKS00021705
Not yet recruiting
Not Applicable

Precalence study on ICU Treatment of COVID-19 patients in Northern and Western Saxony in the first half of 2020 - PraeCoSa - PraeCoSa

Klinik für Anästhesiologie und IntensivtherapieUniversitätsklinikum Leipzig0 sites100 target enrollmentAugust 3, 2020
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsJ12.8J80.09Other viral pneumonia

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
J12.8
Sponsor
Klinik für Anästhesiologie und IntensivtherapieUniversitätsklinikum Leipzig
Enrollment
100
Status
Not yet recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 3, 2020
End Date
TBD
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Klinik für Anästhesiologie und IntensivtherapieUniversitätsklinikum Leipzig

Eligibility Criteria

Inclusion Criteria

  • •positive SARS\-CoV\-2 test result and Treatment in an intensive care unit in the period of January to June 2020

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
Ozone Therapy for Covid 19 patientsHealth Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
CTRI/2020/07/026671Bisleri charitable trust
Not yet recruiting
Not Applicable
Epidemiology and outcomes of COVID-19 in Udupi
CTRI/2020/07/026472Kasturba Medical College Manipal
Not yet recruiting
Not Applicable
A medical records based study for Tou-Jie-Qu-Wen Granules in the Treatment of mild and moderate patients with novel coronavirus pneumonia (COVID-19)COVID-19
ITMCTR2000003144Guangzhou Eighth People's Hospital
Recruiting
Not Applicable
Prospective observational study of COVID-19 patients in the TOKUSHUKAI GROUPThe purpose of this study is to collect information of the clinical course of patients with COVID-19 treated at Tokushukai hospitals with and without antiviral drugs and to explore the clinical course in the acute phase, the frequency of severe disease, and frequency of post COVID-19 condition by the treatment, after adjusting by patient background including risk factor(s) and symptoms at the time of registration.
JPRN-UMIN000053506Shionogi & Co., Ltd.30,000
Not yet recruiting
Phase 3
Effect of COVID-19 convalescent plasma produced by HEMOPE: A randomized study, with a comparative group in several centers
RBR-7jqpnwniversidade de Pernambuco